Definium Therapeutics is a clinical-stage biopharmaceutical company developing novel psychedelic-based therapeutics for brain health disorders, including generalized anxiety disorder, major depressive disorder, and autism spectrum disorder. The company's pipeline centers on two lead candidates: DT120 ODT, a proprietary orally disintegrating tablet formulation of lysergide in Phase 3 development, and DT402, a selective R-enantiomer of MDMA in Phase 2 development. Definium advances its clinical pipeline toward FDA approval, manufactures its compounds through contract partners under licensing arrangements, and aims to commercialize approved products while exploring partnerships and geographic expansion opportunities in major markets.